2-(cyclopropylamino)-1-(4’-chlorophenyl)-1-oxopropane | 1225624-77-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(cyclopropylamino)-1-(4’-chlorophenyl)-1-oxopropane
• 英文别名: 1-(4-Chlorophenyl)-2-(cyclopropylamino)propan-1-one
• CAS: 1225624-77-0
• 化学式: C₁₂H₁₄ClNO
• 分子量: 223.702
• InChiKey: RHQTXFWQMQXRML-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-氯苯丙酮 在 溴 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 18.5h， 生成 2-(cyclopropylamino)-1-(4’-chlorophenyl)-1-oxopropane
  参考文献：
  名称：

  Hybrid Dopamine Uptake Blocker–Serotonin Releaser Ligands: A New Twist on Transporter-Focused Therapeutics

  摘要：

  As part of our program to study neurotransmitter releasers, we report herein a class of hybrid dopamine reuptake inhibitors that display serotonin releasing activity. Hybrid compounds are interesting since they increase the design. potential of transporter related compounds and hence represent a novel and unexplored strategy for therapeutic drug discovery. A series of N-alkylpropiophenones was synthesized and assessed for uptake inhibition and release activity using rat brain synaptosomes. Substitution on the aromatic ring yielded compounds that maintained hybrid activity, with the two disubstituted analogues (PAL-787 and PAL-820) having the most potent hybrid activity.

  DOI：

  10.1021/ml500113s

文献信息

• [EN] MONOAMINE REUPTAKE INHIBITORS<br/>[FR] INHIBITEURS DE LA RECAPTURE DES MONOAMINES
  申请人：RES TRIANGLE INST

  公开号：WO2010121022A1

  公开（公告）日：2010-10-21

  The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.

  该发明提供了一种能够抑制一种或多种单胺再摄取的丁丙吡胺类似化合物。这些化合物可以选择性地结合到一种或多种单胺转运体上，包括多巴胺、去甲肾上腺素和5-羟色胺的转运体。这些化合物可用于治疗对单胺再摄取抑制有响应的疾病，包括成瘾、抑郁和肥胖症。
• MONOAMINE REUPTAKE INHIBITORS
  申请人：Carroll Frank Ivy

  公开号：US20120071560A1

  公开（公告）日：2012-03-22

  The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.

  本发明提供了能够抑制一种或多种单胺再摄取的伯泊隆类似化合物。该化合物可以选择性地结合到一种或多种单胺转运体上，包括多巴胺、去甲肾上腺素和血清素。这种化合物可用于治疗对单胺再摄取抑制有反应的疾病，包括成瘾、抑郁和肥胖症。
• Monoamine reuptake inhibitors
  申请人：Research Triangle Institute

  公开号：US10919841B2

  公开（公告）日：2021-02-16

  The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.

  本发明提供了能够抑制一种或多种单胺再摄取的安非他酮类似物化合物。这些化合物可选择性地与一种或多种单胺转运体结合，包括多巴胺、去甲肾上腺素和血清素的转运体。此类化合物可用于治疗对抑制单胺再摄取有反应的病症，包括成瘾、抑郁症和肥胖症。
• US9562001B2
  申请人：——

  公开号：US9562001B2

  公开（公告）日：2017-02-07
• Hybrid Dopamine Uptake Blocker–Serotonin Releaser Ligands: A New Twist on Transporter-Focused Therapeutics
  作者：Bruce E. Blough、Antonio Landavazo、John S. Partilla、Michael H. Baumann、Ann M. Decker、Kevin M. Page、Richard B. Rothman

  DOI：10.1021/ml500113s

  日期：2014.6.12

  As part of our program to study neurotransmitter releasers, we report herein a class of hybrid dopamine reuptake inhibitors that display serotonin releasing activity. Hybrid compounds are interesting since they increase the design. potential of transporter related compounds and hence represent a novel and unexplored strategy for therapeutic drug discovery. A series of N-alkylpropiophenones was synthesized and assessed for uptake inhibition and release activity using rat brain synaptosomes. Substitution on the aromatic ring yielded compounds that maintained hybrid activity, with the two disubstituted analogues (PAL-787 and PAL-820) having the most potent hybrid activity.